IL269884A - - Google Patents
Info
- Publication number
- IL269884A IL269884A IL26988419A IL26988419A IL269884A IL 269884 A IL269884 A IL 269884A IL 26988419 A IL26988419 A IL 26988419A IL 26988419 A IL26988419 A IL 26988419A IL 269884 A IL269884 A IL 269884A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C62/08—Saturated compounds containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/42—Separation; Purification; Stabilisation; Use of additives
- C07C51/47—Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/305—Saturated compounds containing more than one carboxyl group containing ether groups, groups, groups, or groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762486728P | 2017-04-18 | 2017-04-18 | |
| US201762486822P | 2017-04-18 | 2017-04-18 | |
| US201762569358P | 2017-10-06 | 2017-10-06 | |
| US201762584576P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/028113 WO2018195163A1 (en) | 2017-04-18 | 2018-04-18 | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL269884A true IL269884A (cg-RX-API-DMAC7.html) | 2019-11-28 |
| IL269884B1 IL269884B1 (en) | 2023-05-01 |
| IL269884B2 IL269884B2 (en) | 2023-09-01 |
Family
ID=63791570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL269884A IL269884B2 (en) | 2017-04-18 | 2018-04-18 | Gamkaban its accepted pharmaceutical salts, their compositions and methods of their use |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20180297929A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612171A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2020516622A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20200054910A (cg-RX-API-DMAC7.html) |
| CN (1) | CN110996928A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3059073A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL269884B2 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201902471A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018195163A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| JP2022505033A (ja) * | 2018-10-18 | 2022-01-14 | ジェムフィアー セラピューティクス インコーポレイテッド | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 |
| US20240226049A1 (en) * | 2023-01-09 | 2024-07-11 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
| WO2024151311A1 (en) * | 2023-01-09 | 2024-07-18 | Esperion Therapeutics, Inc. | Methods of treatment using bempedoic acid |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2033909A (en) | 1934-12-19 | 1936-03-17 | Niacet Chemicals Corp | Manufacture of calcium levulinate |
| CA1197242A (en) * | 1983-03-02 | 1985-11-26 | Jean A. Gauthier | Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives |
| US4691034A (en) | 1986-04-14 | 1987-09-01 | Texaco, Inc. | Purification of propylene oxide by treatment with calcium hydroxide in glycerol or sugar water |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| EP1017390B1 (en) | 1997-07-31 | 2007-04-18 | Kos Life Sciences, Inc. | Coated tablet comprising nicotinic acid or a compound metabolized to nicotinic acid in an extended release form, and a coating containing an hmg-coa reductase inhibitor in an immediate release form |
| US6861555B2 (en) * | 2000-01-25 | 2005-03-01 | Warner-Lambert Company | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US6459003B1 (en) | 1999-04-01 | 2002-10-01 | Esperion Therapeutics, Inc. | Ether compounds |
| NZ519550A (en) | 2000-01-25 | 2003-11-28 | Warner Lambert Co | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| CN100376570C (zh) | 2000-10-13 | 2008-03-26 | 希拉生物化学股份有限公司 | 改善胞间传输的二氧戊环类似物 |
| HUP0400381A2 (hu) | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái |
| US20040192771A1 (en) | 2001-10-11 | 2004-09-30 | Dasseux Jean-Louis Henri | Ether compounds and compositions for cholesterol management and related uses |
| DE10211289A1 (de) | 2002-03-14 | 2003-09-25 | Basf Ag | Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität |
| WO2003088962A1 (en) | 2002-04-16 | 2003-10-30 | Merck & Co., Inc. | Combination therapy using a ppar alpha/gamma agonist |
| AU2003227691B2 (en) | 2002-05-03 | 2008-05-15 | Hexal Ag | Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor |
| JP2006501238A (ja) | 2002-08-22 | 2006-01-12 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | 骨関節炎を治療する方法 |
| WO2004045596A1 (en) | 2002-11-15 | 2004-06-03 | Warner-Lambert Company Llc | Method of lowering crp and reducing systemic inflammation |
| ES2645930T3 (es) | 2003-01-03 | 2017-12-11 | Supernus Pharmaceuticals, Inc. | Utilización de una mezcla de dos o más materiales entéricos para regular la liberación de fármacos a través de una membrana o matriz para terapias sistémicas |
| WO2005002557A1 (en) | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050026979A1 (en) | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| US7345190B2 (en) | 2003-11-12 | 2008-03-18 | Ssv Therapeutics, Inc. | Carnitine conjugates as dual prodrugs and uses thereof |
| WO2006054308A2 (en) | 2004-11-22 | 2006-05-26 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| CA2628666A1 (en) | 2005-11-21 | 2007-05-24 | Teva Pharmaceutical Industries Ltd. | Atorvastatin formulation |
| CN104825397A (zh) | 2006-04-03 | 2015-08-12 | 伊萨·奥迪迪 | 含有机溶胶涂层的受控释放递送物件 |
| US7777071B2 (en) | 2006-08-11 | 2010-08-17 | Ssv Therapeutics, Inc. | Production of carnitine conjugate intermediates |
| US20080241240A1 (en) | 2006-08-24 | 2008-10-02 | Hanall Pharmaceutical Co., Ltd. | Combined pharmaceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors |
| WO2008022932A2 (en) | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
| FI20080353A0 (fi) | 2008-05-09 | 2008-05-09 | Atacama Labs Oy | Prosessi erittäin korkean lääkepitoisuuden tabletin valmistamiseksi |
| US9486446B2 (en) | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| CZ300047B6 (cs) | 2007-03-02 | 2009-01-21 | Zentiva, A. S. | Farmaceutická kompozice s obsahem úcinné látky atorvastatinu |
| WO2008124505A2 (en) | 2007-04-05 | 2008-10-16 | Ironwood Pharmaceuticals,Inc. | Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US20090036414A1 (en) | 2007-08-02 | 2009-02-05 | Mutual Pharmaceutical Company, Inc. | Mesalamine Formulations |
| WO2009024889A2 (en) | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
| WO2009048938A1 (en) | 2007-10-08 | 2009-04-16 | Keen Ingredients, Inc. | Quinoa grain processing and products |
| BRPI0822026B8 (pt) | 2008-01-10 | 2021-05-25 | Evonik Roehm Gmbh | preparação farmacêutica ou nutracêutica, comprimido, gelatina ou cápsula de hpmc, e uso de uma ou uma mistura de uma pluralidade de polímeros ou copolímeros |
| US20090226515A1 (en) | 2008-03-04 | 2009-09-10 | Pharma Pass Ii Llc | Statin compositions |
| FR2928925B1 (fr) | 2008-03-19 | 2011-01-07 | Centre Nat Rech Scient | Complexes de bore ou d'aluminium, et leurs utilisations. |
| EP2285352A2 (en) | 2008-05-13 | 2011-02-23 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
| RU2010151944A (ru) | 2008-05-20 | 2012-06-27 | Серенис Терапьютикс С.А. (Fr) | Ниацин и нспвс для комбинированной терапии |
| RU2404767C1 (ru) | 2009-08-11 | 2010-11-27 | Закрытое Акционерное Общество "БИОКОМ" | Твердая лекарственная форма, обладающая гиполипидемической и гипохолестеринемической активностью, и способ ее получения |
| AU2011270719B2 (en) | 2010-06-24 | 2015-09-24 | Arisaph Pharmaceuticals, Inc. | Niacin mimetics, and methods of use thereof |
| TR201005325A2 (tr) | 2010-06-30 | 2012-01-23 | Bi̇lgi̇ç Mahmut | Atorvastatin ve aspirin içeren farmasötik formülasyonlar |
| PL2592081T3 (pl) | 2010-07-06 | 2017-07-31 | Ono Pharmaceutical Co., Ltd. | Pochodna tetrahydrokarboliny |
| TW201304823A (zh) | 2010-12-27 | 2013-02-01 | Takeda Pharmaceutical | 口腔內崩壞錠 |
| ES2608177T3 (es) | 2010-12-27 | 2017-04-06 | Gemphire Therapeutics Inc. | Gemcabeno y derivados para el tratamiento de la pancreatitis |
| UA112539C2 (uk) | 2011-03-03 | 2016-09-26 | Новартіс Аг | Спосіб одержання похідних 2-карбоксамідциклоаміносечовини |
| CA2835293C (en) * | 2011-06-08 | 2020-08-18 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| RU2491070C2 (ru) | 2011-10-11 | 2013-08-27 | Общество с ограниченной ответственностью "Фармамед" | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний |
| EP2787986B1 (en) | 2011-12-08 | 2017-10-18 | Syndromex Ltd. | Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof |
| EP2604256B1 (en) | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| JP6295205B2 (ja) * | 2012-01-06 | 2018-03-14 | ジェムファイア セラピューティクス インクGemphire Therapeutics Inc. | 心血管疾患のリスクを低減する方法 |
| CN104127391B (zh) | 2014-08-05 | 2016-08-24 | 李宝齐 | 一种含有阿托伐他汀钙的固体药物组合物 |
| EP3218349A2 (en) * | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| MX2018005096A (es) * | 2015-11-06 | 2018-08-15 | Gemphire Therapeutics Inc | Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular. |
| CN105434391A (zh) | 2016-01-18 | 2016-03-30 | 上海蓝心医药科技有限公司 | 阿托伐他汀钙肠溶片及其制备方法和应用 |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| WO2018209257A1 (en) | 2017-05-11 | 2018-11-15 | Gemphire Therapeutics Inc. | Gemcabene compositions and methods of use thereof |
-
2018
- 2018-04-18 EP EP18788278.2A patent/EP3612171A4/en not_active Withdrawn
- 2018-04-18 WO PCT/US2018/028113 patent/WO2018195163A1/en not_active Ceased
- 2018-04-18 TW TW107113223A patent/TW201902471A/zh unknown
- 2018-04-18 CA CA3059073A patent/CA3059073A1/en active Pending
- 2018-04-18 IL IL269884A patent/IL269884B2/en unknown
- 2018-04-18 KR KR1020197031929A patent/KR20200054910A/ko not_active Withdrawn
- 2018-04-18 US US15/956,172 patent/US20180297929A1/en not_active Abandoned
- 2018-04-18 JP JP2019555180A patent/JP2020516622A/ja active Pending
- 2018-04-18 CN CN201880040555.5A patent/CN110996928A/zh active Pending
-
2019
- 2019-05-03 US US16/402,853 patent/US20200148617A1/en not_active Abandoned
-
2022
- 2022-01-24 US US17/583,081 patent/US12503422B2/en active Active
-
2023
- 2023-01-26 JP JP2023010250A patent/JP2023057082A/ja active Pending
-
2025
- 2025-11-21 US US19/397,103 patent/US20260209157A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023057082A (ja) | 2023-04-20 |
| KR20200054910A (ko) | 2020-05-20 |
| IL269884B2 (en) | 2023-09-01 |
| JP2020516622A (ja) | 2020-06-11 |
| CN110996928A (zh) | 2020-04-10 |
| TW201902471A (zh) | 2019-01-16 |
| US20200148617A1 (en) | 2020-05-14 |
| US20180297929A1 (en) | 2018-10-18 |
| IL269884B1 (en) | 2023-05-01 |
| EP3612171A1 (en) | 2020-02-26 |
| EP3612171A4 (en) | 2020-10-21 |
| US20260209157A1 (en) | 2026-07-23 |
| US20220332672A1 (en) | 2022-10-20 |
| US12503422B2 (en) | 2025-12-23 |
| CA3059073A1 (en) | 2018-10-25 |
| WO2018195163A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR122021000189A2 (cg-RX-API-DMAC7.html) | ||
| BR112019008823A2 (cg-RX-API-DMAC7.html) | ||
| BR112020006084A8 (cg-RX-API-DMAC7.html) | ||
| BR112019025875B1 (pt) | Sistema de cilindro com estrutura de ocupação de movimento relativo | |
| BR112020011860B1 (pt) | Dispositivo cirúrgico para cortar uma lente dentro de um saco capsular de um olho | |
| BR112020006283B1 (pt) | Placa refinadora, e, refinador para tratamento mecânico de material orgânico/celulósico | |
| BR112020009729B1 (pt) | Inibidores de acss2 e métodos de uso dos mesmos | |
| BR112020008714B1 (pt) | Uso de medicamentos serotoninérgicos para tratar trombocitopenia induzida por vírus | |
| BR112020006992B1 (pt) | Dispositivo de recolhimento e método para o recolhimento de uma embarcação | |
| BR112019023976B1 (pt) | Sistema e método para comunicar dados de saúde em um ambiente de cuidados de saúde | |
| BR112020002577B1 (pt) | Método de melhoria de rendimento de centrifugação dupla para purificação de óleo nutritivo | |
| BR112019016885B1 (pt) | Remodelagem de imagem integrada e codificação de vídeo | |
| BR112020001354B1 (pt) | Método, em uma primeira estação base, para suportar posicionamento de um dispositivo móvel e primeira estação base para suportar posicionamento de um dispositivo móvel | |
| BR112019026818B1 (pt) | Método de codificação, método de decodificação, aparelho, aparelho de comunicações, terminal, estação base e mídia legível por computador | |
| BR102018011961B1 (pt) | Sistemas, métodos e meio não transitório legível por computador para analisar cores a partir de uma plataforma de mídia social | |
| BR112019026880B1 (pt) | Método de comunicação, método para receber dados, e, dispositivo | |
| BR112019023944B1 (pt) | Combinação farmacêutica para o tratamento de um câncer | |
| BR112019021396B1 (pt) | Processo para fabricação de pululano | |
| BR112019016182B1 (pt) | Método para diagnosticar risco de revisão relacionado a implante | |
| BR112019014127B1 (pt) | Composição farmacêutica para tratamento de tumores | |
| BR112019017156B1 (pt) | Dispositivo, sistema e método de gerenciamento de recepção de pedido, e, meio de armazenamento legível por computador | |
| BR112019014017B1 (pt) | Dispositivo de medição da quantidade de oxigênio presente em um gás, e, módulo de separação de ar | |
| BR102017026429B1 (pt) | Método de extração subsequente de ácidos graxos e dna genômico a partir de dípteros | |
| BR112020009084B1 (pt) | Método de operação de um nó de rádio alvo, nó de rádio alvo, método de operação de um nó de rádio de transmissão, nó de rádio de transmissão, e, meio de armazenamento não transitório legível por computador | |
| BR112020008456B1 (pt) | Terminal e método de transmissão para um terminal |